Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
暂无分享,去创建一个
Martin Eisenacher | Maike Ahrens | Stefan Welter | Felix Nensa | Martin Schuler | Andreas-Claudius Hoffmann | Jens Köhler | K. Darwiche | J. Köhler | F. Nensa | T. Gauler | M. Eisenacher | M. Schuler | W. Schmiegel | H. Reis | S. Hahn | S. Kasper | F. Breitenbuecher | A. Baraniskin | W. Eberhardt | H. Teschler | Wolff Schmiegel | Helmut Teschler | Henning Reis | Kaid Darwiche | Georgios Stamatis | G. Stamatis | Benedikt Gomez | Stefan Kasper | S. Welter | Thomas Christoph Gauler | Stefanie Nöpel-Dünnebacke | Maria Hahnemann | Frank Breitenbuecher | Danjouma Cheufou | Filiz Özkan | Mathias Hoiczyk | Wilfried Ernst Erich Eberhardt | Stephan Albrecht Hahn | Alexander Baraniskin | S. Nöpel-Dünnebacke | A. Hoffmann | D. Cheufou | B. Gomez | M. Hoiczyk | M. Hahnemann | M. Ahrens | F. Özkan
[1] H. Matsubara,et al. Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma , 2013, British Journal of Cancer.
[2] M. Nykter,et al. Circulating Plasma MiR-141 Is a Novel Biomarker for Metastatic Colon Cancer and Predicts Poor Prognosis , 2011, PloS one.
[3] Michael F. Ochs,et al. Serum microRNA Biomarkers for Detection of Non-Small Cell Lung Cancer , 2012, PloS one.
[4] R. Stephens,et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.
[5] M. Roizen. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[6] Patrick Maisonneuve,et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer , 2011, EMBO molecular medicine.
[7] Ugo Pastorino,et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer , 2011, Proceedings of the National Academy of Sciences.
[8] E. Martens-Uzunova,et al. Beyond microRNA--novel RNAs derived from small non-coding RNA and their implication in cancer. , 2013, Cancer letters.
[9] F. Ardissone,et al. The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases. , 2013, Clinical lung cancer.
[10] C. Andersen,et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma , 2013, International journal of cancer.
[11] Sung-Liang Yu,et al. MicroRNA signature predicts survival and relapse in lung cancer. , 2008, Cancer cell.
[12] R. Kimmig,et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer. , 2014, Clinical chemistry.
[13] L. Paz-Ares,et al. MicroRNA clusters: dysregulation in lung adenocarcinoma and COPD , 2014, European Respiratory Journal.
[14] R. Stupp,et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study , 2006, British Journal of Cancer.
[15] Bengt Bergman,et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. , 2004, The New England journal of medicine.
[16] A. Didier,et al. Alternative Processing of the U2 Small Nuclear RNA Produces a 19–22nt Fragment with Relevance for the Detection of Non-Small Cell Lung Cancer in Human Serum , 2013, PloS one.
[17] Martin Löwer,et al. Digital Genome-Wide ncRNA Expression, Including SnoRNAs, across 11 Human Tissues Using PolyA-Neutral Amplification , 2010, PloS one.
[18] You Lu,et al. Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local Control in Non–Small-Cell Lung Cancer Receiving Radiotherapy , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] X. Liu,et al. Expression of miR-29c, miR-93, and miR-429 as Potential Biomarkers for Detection of Early Stage Non-Small Lung Cancer , 2014, PloS one.
[20] P. Wimberger,et al. Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients , 2015, Clinical chemistry and laboratory medicine.
[21] R. Cerfolio,et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. , 2004, The Annals of thoracic surgery.
[22] R. Hubbard,et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. , 2000, American journal of respiratory and critical care medicine.
[23] H. Hoogsteden,et al. SUVmax during 18FDG-PET scanning in small cell lung cancer: similar information as in non-small cell lung cancer? , 2012, Lung cancer.
[24] P. Mazzone,et al. Analysis of volatile organic compounds in the exhaled breath for the diagnosis of lung cancer. , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[25] J. Crowley,et al. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] The blood-borne miRNA signature of lung cancer patients is independent of histology but influenced by metastases , 2014, Molecular Cancer.
[27] A. Agustí,et al. Chronic obstructive pulmonary disease and risk of lung cancer: the importance of smoking and timing of diagnosis. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[28] O. Miettinen,et al. Survival of Patients with Stage I Lung Cancer Detected on CT Screening , 2008 .
[29] T. Tammela,et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.
[30] Chadwick M. Hales,et al. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease , 2013, Proceedings of the National Academy of Sciences.
[31] W. Schmiegel,et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. , 2016, Neuro-oncology.
[32] D. Postma,et al. Unravelling the complexity of COPD by microRNAs: it's a small world after all , 2015, European Respiratory Journal.
[33] M. L. Hastings,et al. Selective Release of MicroRNA Species from Normal and Malignant Mammary Epithelial Cells , 2010, PloS one.
[34] Aaron A Hoskins,et al. The spliceosome: a flexible, reversible macromolecular machine. , 2012, Trends in biochemical sciences.
[35] Daniel B. Martin,et al. Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.
[36] B. Sitek,et al. Analysis of U2 Small Nuclear RNA Fragments in the Bile Differentiates Cholangiocarcinoma from Primary Sclerosing Cholangitis and Other Benign Biliary Disorders , 2014, Digestive Diseases and Sciences.